Build the regulated future of addiction recovery with us.
RESET works with clinical research partners, manufacturers, institutional investors, and strategic partners. The category will be defined by the first credible, compliance-first operators — and that is what we are building.
If you are building the regulated future of recovery.
RESET works with four categories of partner. Each is brought into the operating discipline of the platform.
Clinical research partners
Sponsors, CROs, investigator sites seeking disciplined, GMP-aligned investigational supply and well-designed protocols.
Manufacturing partners
Evaluating a serious, well-capitalised counterparty for partner-branded clinical research supply.
Institutional & strategic
Investors and strategic partners seeking exposure to addiction-recovery neurotherapeutics through a compliance-first vehicle.
Medical & regulatory
Professionals with diligence questions about a specific programme or our operating discipline.
Compliance, brand, optionality, timing.
Four reasons the first credible, compliance-first operator wins this category.
Compliance as the moat
The most regulatable operator holds the durable advantage in a regulated category.
Brand as infrastructure
Physician and institutional confidence is a real asset. RESET is engineered to earn it.
Optionality, not single-asset risk
A platform brand for the field; multiple investigational compounds and protocols can plug in.
This material is for informational purposes only and does not constitute an offer of securities, investment advice, or a solicitation in any jurisdiction. Forward-looking statements involve risk and uncertainty; outcomes in a regulated, pre-approval category cannot be assured.
Build the regulated future of addiction recovery with us.
Science. Compassion. Transformation. RESET is a clinical-stage neurotherapeutics company — partner with the discipline behind a new era of recovery research.